Evidence map›Paper›PMID 32253718›Full record

ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2020

Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.

Stephanie L Ho, Fang Niu, Suresh Pola, Fernando S Velayos, Xian Ning, Rita L Hui

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Stephanie L HoDrug Use Management, Kaiser Permanente, Oakland, CA, USA.
Fang NiuPharmacy Outcomes Research Group, Kaiser Permanente, Downey, CA, USA.
Suresh PolaDepartment of Gastroenterology, Southern California Permanente Medical Group, San Diego, CA, USA.
Fernando S VelayosDivision of Gastroenterology and Hepatology, The Permanente Medical Group, San Francisco, CA, USA.
Xian NingDrug Use Management, Kaiser Permanente, Oakland, CA, USA.
Rita L HuiPharmacy Outcomes Research Group, Kaiser Permanente, 1800 Harrison St #1301, Oakland, CA, 94612, USA. Rita.L.Hui@kp.org.ORCID 0000-0003-0014-2431

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study, written by Stephanie L. Ho, Fang Niu, Suresh Pola, Fernando S. Velayos, Xian Ning and Rita L. Hui, was originally published electronically on 26 February 2020 without open access.

Identifiers

PMID32253718
PMCPMC7211201

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.